Close Menu

NEW YORK – The European Commission has approved alpelisib (Novartis' Piqray) in combination with fulvestrant for the treatment of post-menopausal women, and men, with hormone receptor- and HER2-positive advanced or metastatic breast cancer with PIK3CA mutations. Patients must have progressed on endocrine therapy first.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.